What is Leerink Partnrs’ Estimate for TNGX Q1 Earnings?

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Leerink Partnrs issued their Q1 2025 EPS estimates for Tango Therapeutics in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will post earnings per share of ($0.32) for the quarter. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share. Leerink Partnrs also issued estimates for Tango Therapeutics’ Q2 2025 earnings at ($0.36) EPS and Q4 2025 earnings at ($0.31) EPS.

A number of other research analysts have also weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Tango Therapeutics in a report on Thursday, December 5th. B. Riley lowered their price target on Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, November 11th. HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of Tango Therapeutics in a research report on Friday, November 8th. Finally, Guggenheim lowered their price target on Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $13.14.

Tango Therapeutics Stock Performance

TNGX stock opened at $3.03 on Friday. The firm has a fifty day moving average price of $3.12 and a 200 day moving average price of $6.10. Tango Therapeutics has a fifty-two week low of $2.59 and a fifty-two week high of $12.80. The firm has a market cap of $325.48 million, a PE ratio of -2.57 and a beta of 0.80.

Institutional Investors Weigh In On Tango Therapeutics

A number of institutional investors have recently added to or reduced their stakes in TNGX. Dimensional Fund Advisors LP boosted its holdings in shares of Tango Therapeutics by 42.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 335,913 shares of the company’s stock valued at $2,882,000 after buying an additional 100,257 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Tango Therapeutics by 8.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 29,511 shares of the company’s stock worth $253,000 after buying an additional 2,218 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Tango Therapeutics in the 3rd quarter worth approximately $151,000. China Universal Asset Management Co. Ltd. grew its position in shares of Tango Therapeutics by 64.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,607 shares of the company’s stock worth $159,000 after buying an additional 8,055 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new position in shares of Tango Therapeutics in the 3rd quarter worth approximately $349,000. Institutional investors own 78.99% of the company’s stock.

Insider Transactions at Tango Therapeutics

In related news, CEO Barbara Weber sold 9,778 shares of Tango Therapeutics stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total transaction of $29,236.22. Following the transaction, the chief executive officer now directly owns 1,631,264 shares of the company’s stock, valued at $4,877,479.36. This trade represents a 0.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Mace Rothenberg bought 10,000 shares of the stock in a transaction on Monday, November 18th. The shares were bought at an average price of $3.78 per share, with a total value of $37,800.00. Following the acquisition, the director now owns 31,250 shares of the company’s stock, valued at $118,125. This trade represents a 47.06 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 24,268 shares of company stock worth $72,561. 6.30% of the stock is currently owned by insiders.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.